Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
Introduction: Imatinib Mesylate is a selective inhibitor of TK and is considered now to be the frontline therapeutic agent during the chronic phase of CML. We have evaluated the efficacy of it on children with chronic-phase of CML. Patients and Methods: In a clinical trial study over the past 3 year...
| Príomhchruthaitheoirí: | , , |
|---|---|
| Formáid: | Alt |
| Teanga: | English |
| Foilsithe / Cruthaithe: |
Tehran University of Medical Sciences
2009-09-01
|
| Sraith: | International Journal of Hematology-Oncology and Stem Cell Research |
| Ábhair: | |
| Rochtain ar líne: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/217 |